About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

Latest News

Innocoll to Partner with Mallinckrodt Acute Care Sales Team to Support the Launch of XARACOLL® (bupivacaine HCl) implant

Mallinckrodt’s hospital sales force to begin promoting recently approved XARACOLL®, a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCI...
Read More

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

XARACOLL is a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCl directly to the surgical site providing long-lasting pain...
Read More

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain

- FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of August 26, 2020- ATHLONE, Ireland, March 26, 2020...
Read More